Dr. Busch MVZ GmbH
- Address
- Bei Der Marienkirche 6, 99974 Muehlhausen/thueringen, Germany
Dr. Busch MVZ GmbH - Breast Cancer Research Center
Dr. Busch MVZ GmbH is a specialized medical research center with extensive expertise in breast cancer clinical trials, particularly focusing on early-stage disease and innovative treatment approaches. The center demonstrates comprehensive experience across multiple therapeutic modalities, including immunotherapy, targeted therapy, and precision medicine strategies.
- Triple-negative breast cancer research combining immunotherapy with neoadjuvant and adjuvant chemotherapy regimens
- Hormone receptor-positive (ER+/HER2-) breast cancer studies utilizing novel endocrine therapies and ctDNA monitoring
- BRCA-mutated breast cancer trials investigating PARP inhibitor therapy in high-risk patient populations
The center's research portfolio emphasizes personalized treatment strategies in breast cancer management, ranging from immunotherapy combinations in aggressive disease subtypes to biomarker-driven approaches using circulating tumor DNA (ctDNA) for treatment selection. Their participation in Phase III trials investigating adjuvant and neoadjuvant therapies positions them at the forefront of developing evidence-based treatment protocols aimed at improving event-free survival and distant metastasis-free survival outcomes for breast cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dr. Busch MVZ GmbH
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease | Gilead Sciences Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 1 | Unknown | 2024-02-23 | 2024-02-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.